Capital Health Regional Medical Center is a member of Capital Health System. Located in Trenton, New Jersey, Capital Health Regional Medical Center, is a regional academic medical center and state designated trauma center that cares for both complex and routine cases.

There are 265 beds in Capital Health.

During the past decade, Capital Health conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 6 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Capital Health" #1 sponsor was "Radiation Therapy Oncology Group" with 3 trials, followed by "Atox Bio Ltd" with 2 trials sponsored, "Stryker Neurovascular" with 2 trials sponsored, "Accuray Incorporated" with 1 trials sponsored and "Angiodynamics, Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Capital Health" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "NRG Oncology" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Capital Health" are "Prostate Cancer" (4 trials), "Breast Cancer" (2 trials), "Ischemic Stroke" (2 trials), "Acute Kidney Injury" (1 trials) and "Cancer of the Prostate" (1 trials). Many other conditions were trialed in "Capital Health" in a lesser frequency.

Most popular intervention types in "Capital Health" are "Drug" (9 trials), "Radiation" (4 trials), "Device" (3 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (3 trials), "Placebo" (2 trials), "AB103 0.5 mg/kg" (1 trials), "Apixaban 2.5 MG" (1 trials) and "CyberKnife Stereotactic Radiosurgery" (1 trials). Other intervention names were less common.

The vast majority of trials in "Capital Health" are 11 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Capital Health". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Capital Health, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Capital Health, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".